Targeted drug duo tested for Tough-to-Treat prostate cancer
NCT ID NCT03360721
Summary
This study tested whether combining two drugs, apalutamide and abiraterone acetate, could better control advanced prostate cancer that had spread and stopped responding to standard hormone therapy. It aimed to see if this combination could slow the cancer's growth in men whose tumors had a specific biological signature. The trial was small and ended early, so its findings are limited.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IVB PROSTATE CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.